Drug Trial Radar · NCT06150014
A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B
Last checked: Nov 19, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
88
Actual
Start
Dec 7, 2023
Primary completion
Dec 2025
Study completion Sep 2026
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind Phase Ib/IIa multicenter trial design was used. All eligible subjects received TQA3605 tablets/placebo plus nucleoside (acid) analogues. A total of 88 subjects were required
Conditions
- Chronic Hepatitis b
Interventions
PlaceboDrug
TQA3605 placebo tablets were orally administered on an empty stomach (at least 2 hours before or after meals) with warm.
TQA3605 tabletsDrug
TQA3605 inhibits viral replication.
Entecavir dispersible tabletsDrug
Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.
Tenofovir disoproxil fumarate tabletDrug
Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.
Tenofovir alafenamide fumarate tabletDrug
Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of adverse events (AEs)Time frame: Up to 48 weeks
- Severity of adverse events (AEs)Time frame: Up to 48 weeks
- Incidence of serious adverse events (SAEs)Time frame: Up to 48 weeks
- Severity of serious adverse events (SAEs)Time frame: Up to 48 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shannxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.